Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).

被引：6
|
作者：
Bahlis, Nizar J.
Moreau, Philippe
Nahi, Hareth
Plesner, Torben
Goldschmidt, Hartmut
Suzuki, Kenshi
Orlowski, Robert Z.
Rabin, Neil
Leiba, Merav
Oriol, Albert
Chari, Ajai
Miguel, Jesus San
Richardson, Paul G.
Usmani, Saad Zafar
O'Rourke, Lisa Marie
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Qin, Xiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8025
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).
    Lentzsch, Suzanne
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Hungria, Vania
    Munder, Markus
    Nooka, Ajay K.
    Mark, Tomer
    Quach, Hang
    Scott, Emma Catherine
    Lee, Je-Jung
    Sonneveld, Pieter
    Casneuf, Tineke
    Chiu, Christopher
    Qin, Xiang
    Amin, Himal
    Thiyagarajah, Piruntha
    Schecter, Jordan Mark
    Qi, Ming
    Spencer, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    White, Darrell
    LeBlanc, Richard
    Venner, Chritopher
    Bahlis, Nizar J.
    Lentzsch, Suzanne
    Gasparetto, Cristina J.
    Chen, Christine
    Lipe, Brea
    Sutherland, Heather
    Tuchman, Sascha
    Baljevic, Muhamed
    Kotb, Rami
    Sebag, Michael
    Callander, Nancy
    Bensinger, William
    Kai, Kazuharu
    Liu, Jianjun
    Sheehan, Heidi
    Estepan, Daniel Nova
    Shah, Jatin
    Schiller, Gary J.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E55 - E55
  • [23] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
    Weisel, Katja C.
    Miguel, Jesus San
    Cook, Gordon
    Leiba, Merav
    Suzuki, Kenshi
    Kumar, Shaji
    Cavo, Michele
    Avet-Loiseau, Herve
    Quach, Hang
    Hungria, Vania
    Lentzsch, Suzanne
    Hajek, Roman
    Sonneveld, Pieter
    Wu, Kaida
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    San-Miguel, J.
    Weisel, K.
    Cook, G.
    Leiba, M.
    Suzuki, K.
    Kumar, S.
    Cavo, M.
    Avet-Loiseau, H.
    Quach, H.
    Hungria, V.
    Lentzsch, S.
    Hajek, R.
    Sonneveld, P.
    Wu, K.
    Qin, X.
    Chiu, C.
    Soong, D.
    Qi, M.
    Schecter, J.
    Dimopoulos, M. A.
    [J]. HAEMATOLOGICA, 2017, 102 : 1 - 2
  • [25] Addition of daratumumab to the combination of lenalidomide and dexamethasone in relapsed or refractory myeloma
    Stocker, Nicolas
    [J]. HEMATOLOGIE, 2019, 25 (01): : 10 - 11
  • [26] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    [J]. Leukemia, 2020, 34 : 3286 - 3297
  • [27] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    [J]. LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [28] Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
    M A Dimopoulos
    A K Stewart
    T Masszi
    I Špička
    A Oriol
    R Hájek
    L Rosiñol
    D Siegel
    G G Mihaylov
    V Goranova-Marinova
    P Rajnics
    A Suvorov
    R Niesvizky
    A Jakubowiak
    J San-Miguel
    H Ludwig
    S Ro
    S Aggarwal
    P Moreau
    A Palumbo
    [J]. Blood Cancer Journal, 2017, 7 : e554 - e554
  • [29] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
  • [30] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Dimopoulos, M. A.
    Oriol, A.
    Nahi, H.
    San-Miguel, J.
    Bahlis, N. J.
    Usmani, S. Z.
    Rabin, N.
    Orlowski, R. Z.
    Komarnicki, M.
    Suzuki, K.
    Plesner, T.
    Yoon, S. -S.
    Ben Yehuda, D.
    Richardson, P. G.
    Goldschmidt, H.
    Reece, D.
    Lisby, S.
    Khokhar, N. Z.
    O'Rourke, L.
    Chiu, C.
    Qin, X.
    Guckert, M.
    Ahmadi, T.
    Moreau, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14): : 1319 - 1331
12345